Unknown

Dataset Information

0

A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia.


ABSTRACT: Fanconi anemia (FA)-mutated acute myeloid leukemia (AML) is a secondary AML with very poor prognosis and limited therapeutic options due to increased sensitivity to DNA-damaging agents. PD-1 immune checkpoint inhibitors upregulate T-cell killing of cancer cells and is a class of promising treatment for FA-AML. Here, we developed a novel FA-AML murine model that allows the study of human AML with a humanized immune system in order to investigate immunotherapeutic treatments in vivo. FA-AML1 cells and non-FA-mutated Kasumi-1 cells were injected into 8-10 week old NSG mice. Once leukemic engraftment was confirmed by HLA-DR expression in the peripheral blood, human peripheral blood mononuclear cells (hPBMCs) were injected into the mice. One week post-hPBMCs injection, Nivolumab (PD-1 inhibitor) or PBS vehicle control was administered to the mice bi-weekly. In our Nivolumab treated mice, FA-AML1, but not Kasumi-1-engrafted mice, had significantly prolonged overall survival. Both FA-AML1 and Kasumi-1 engrafted mice had decreased spleen weights. Higher leukemic infiltration into vital organs was observed in FA-AML1 engrafted mice compared to Kasumi-1 engrafted mice. In conclusion, our novel humanized murine model of FA-mutated AML is an attractive tool for supporting further studies and clinical trials using PD-1 inhibitors to treat FA-mutated AML.

SUBMITTER: Huang T 

PROVIDER: S-EPMC10826936 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

altmetric image

Publications

A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia.

Huang Tingting T   Leung Bernice B   Huang Yuyang Y   Price Laura L   Gui Jiang J   Lau Bonnie W BW  

PloS one 20240130 1


Fanconi anemia (FA)-mutated acute myeloid leukemia (AML) is a secondary AML with very poor prognosis and limited therapeutic options due to increased sensitivity to DNA-damaging agents. PD-1 immune checkpoint inhibitors upregulate T-cell killing of cancer cells and is a class of promising treatment for FA-AML. Here, we developed a novel FA-AML murine model that allows the study of human AML with a humanized immune system in order to investigate immunotherapeutic treatments in vivo. FA-AML1 cells  ...[more]

Similar Datasets

| S-EPMC6071325 | biostudies-literature
| S-EPMC6002376 | biostudies-literature
| S-EPMC4653013 | biostudies-literature
| S-EPMC6355238 | biostudies-literature
2024-12-09 | MSV000096625 | MassIVE
| S-EPMC8419016 | biostudies-literature
| S-EPMC10655686 | biostudies-literature
| S-EPMC8159924 | biostudies-literature
| S-EPMC7920435 | biostudies-literature
2021-03-25 | GSE169586 | GEO